Unlocking Undruggable Targets to Treat Cancer

Our peptide inhibitors of intracellular protein-protein interactions are designed to attack previously “undruggable targets” in cancer cells, promoting cancer cell death or immune-modulations.

Get to Know Us
Translating Science into Novel Therapeutics

Translating Science into Novel Therapeutics

Our discovery platform provides drug candidates that target specific protein-protein interactions responsible for transcriptional regulation of oncogenic and immune-modulatory proteins.

Discovery Platform
ST101 for the Treatment of Solid Tumors

ST101 for the Treatment of Solid Tumors

Our lead candidate, ST101, is peptide antagonist of C/EBPβ that was designed to promote cell death of solid tumors including breast cancer, melanoma, prostate cancer, and GBM, as well as hematologic malignancies.

How ST101 Works
Science Backed by Strong Leadership

Science Backed by Strong Leadership

Our world-class team is helping us pave the way to providing therapeutics for major unmet medical needs.

View Leadership